Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels.

@article{Aymard1997NeurolepticresistantSP,
  title={Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels.},
  author={Nicole Aymard and Chiara Baldacci and A. Leyris and P. O. Smagghe and Serge Tribolet and Marie No{\"e}lle Vacheron and Annie Viala and François Caroli},
  journal={Therapie},
  year={1997},
  volume={52 3},
  pages={
          227-32
        }
}
The aim of this open study was to determine a more rational therapeutic approach for psychotic patients treated with clozapine for several months, using measurement of plasma and red blood cell levels (P, RBC) of clozapine (cloza) and N-desmethylclozapine (descloza), the major metabolite of clozapine, which has been reported to be less active but more toxic (agranulocytosis) than clozapine itself. The RBC concentration may be considered as more representative of the free fraction drug. The… CONTINUE READING